Published on 28 May 2024 on Zacks via Yahoo Finance
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Exact Sciences Corporation EXAS will present 10 abstracts demonstrating the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 31 to Jun 4, 2024. The data that will be provided expands the body of evidence surrounding the predictive and prognostic utility of the Oncotype DX test in all racial and ethnically diverse patients.
Exact Sciences will also present data on their approach to multi-cancer early detection (MCED) across several tumor types and new real-world evidence demonstrating optimized screening adherence techniques for the Cologuard test and high adherence rates for repeat screening.
Highlights of Data Presented